A series of important meetings are taking place that could decide the fate of upcoming HIV blocking drugs. Pfizer seems to have taken the lead, but there are other Pharmaceutical giants, including Merck which are closing in on HIV inhibitors.
A panel of experts meets in Rockville, Md., to advise the Food and Drug Administration on whether to approve Pfizer's maraviroc to fight HIV. If approved it would be the first in a new class of treatments that block HIV from entering white blood cells through a pathway present in some patients that carry the virus.
There have been numerous research directions that have given moderately successful results - with several candidates for cancer inhibiting markers being discovered. The fight against cancers is not completely won, but the progress has been commendable.
HIV, along with cancer remains the holy grail for the biotechnology world and all advancements in combating them come as great news.
The developments are heartening and the success of this research would not only go a long way in providing a boost to the Pharmaceutical industry,but much more importantly - help in saving lives.
No comments:
Post a Comment